Your Next Customer Isn’t Googling You. They’re Asking AI 
Rhino Propels Federated AI into the Enterprise Tech Stack Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David…
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights
– Second quarter total revenue and government support income increased over 100% year-over-year – –…
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
Pre-launch commercial activities underway as Company advances toward U.S. Food and Drug Administration (FDA) Prescription…
Skillsoft’s Lean Into Learning Report: Changing Nature of Work Leads to Surge in Skilling
Study shows increases in learning consumption across Skillsoft portfolio; highlights in-demand skills and top trends…
Endomimetics™ Announces a Research Collaboration Agreement with BISCO, Inc., to Support Development of a Dental Application of Bionanomatrix™
Funding matches Alabama Research and Development Enhancement Fund (ARDEF) grant to Kyounga Cheon, D.M.D., M.S.,…
Morphic to Present at SVB Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing…
Athenex Announces a Reverse Stock Split
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical…
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global…
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects…
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients…
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Radiopharm Theranostics Initiates Process for Nasdaq Listing
Proposed listing on NASDAQ with RADX ticker symbol Form 20-F registration filed with Securities and…
PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
Intense interest in PharmAla’s best-in-class manufacturing and regulatory excellence continues as PharmAla examines further Australian…
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS),…
AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
Live event scheduled for Friday, February 24th at 11:00 am Eastern Time IRVINE, Calif., Feb….
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN…
Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA Recently…
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule…
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell…